Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2007

01-04-2007 | Original Article

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Authors: Emilio Bajetta, Laura Catena, Giuseppe Procopio, Sara De Dosso, Ettore Bichisao, Leonardo Ferrari, Antonia Martinetti, Marco Platania, Elena Verzoni, Barbara Formisano, Roberto Bajetta

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2007

Login to get access

Abstract

Purpose

The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment.

Methods

Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).

Results

In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.

Conclusions

The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.
Literature
1.
Solcia E, Kloppel G, Sobin LH (2000) Histologic typing of endocrine tumours. WHO international histological classification of tumours. Springer, Berlin Heidelberg New York
2.
Travis WD, Brambilla E, Muller-Hermelink HK, Harris SL (2004) Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, Geneva
3.
Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J (2005) Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16:1374–1380PubMedCrossRef
4.
Artale S, Giannetta L, Cerea G, Pedrazzoli P, Schiavetto I, Napolitano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S (2005) Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Res 25:4463–4469PubMed
5.
Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in anaplastic variance of these neoplasm. Cancer 68:227–232PubMedCrossRef
6.
Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107PubMedCrossRef
7.
Rivera E, Ajani JA (1998) Doxorubicin, streptozotocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin 21:36–38CrossRef
8.
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRef
9.
Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of chemotherapy combinations for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621PubMedCrossRef
10.
Ridolfi R, Amaducci L, Derni S, Fabbri L, Innocenti MP, Vignutelli P (1991) Chemotherapy with 5-fluorouracil and streptozocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients. J Chemother 3:328–331PubMed
11.
Gonzalez MA, Biswas S, Clifton L, Corrie PG (2003) Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89:455–456PubMedCrossRef
12.
Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L (1993) Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon alpha-2. Cancer 72:3099–3105PubMedCrossRef
13.
Tetzlaff ED, Ajani JA (2005) Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer 36:55–58PubMedCrossRef
14.
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO offset publication N. 48, Geneva
15.
Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRef
16.
Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in anaplastic variance of these neoplasm. Cancer 68:227–232PubMedCrossRef
17.
Oberg K (2001) Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12(Suppl 2):S111–S114PubMedCrossRef
18.
Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62:73–78PubMedCrossRef
19.
Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 22:4897–4904CrossRef
20.
Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) group. Ann Oncol 6:77–79PubMed
21.
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRef
22.
Pavel ME, Baum U, Hahn EG, Hensen J (2005) Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 35:179–185PubMedCrossRef
Metadata
Title
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Authors
Emilio Bajetta
Laura Catena
Giuseppe Procopio
Sara De Dosso
Ettore Bichisao
Leonardo Ferrari
Antonia Martinetti
Marco Platania
Elena Verzoni
Barbara Formisano
Roberto Bajetta
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0306-6

Other articles of this Issue 5/2007

Cancer Chemotherapy and Pharmacology 5/2007 Go to the issue

Original Article

Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis

Original Article

In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng

Short Communication

Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas

Original Article

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Original Article

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours

Original Article

Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits